Hainan Sihuan Cardiocerebral Vascular Drugs Research Institute

Hainan Sihuan Cardiocerebral Vascular Drugs Research Institute is the core research and development subsidiary of Sihuan Pharmaceutical Holdings Group, one of China's largest pharmaceutical companies specializing in cardio-cerebral vascular (CCV) treatments. Based in Haikou, the institute focuses on the discovery and clinical development of innovative small molecules and high-end generics across multiple therapeutic areas including oncology, metabolic diseases, and neurology. The facility serves as a critical hub for the group's transition from a CCV-focused manufacturer to a diversified biopharmaceutical innovator. Its efforts have led to the successful development of several late-stage candidates and recently approved drugs like the SGLT2 inhibitor Janagliflozin. The institute integrates chemical synthesis, pharmacology, and formulation research to support the parent company's extensive commercial portfolio.